Tengion, Inc.  

(Public, OTCMKTS:TNGNQ)   Watch this stock  
Find more results for NASDAQ:TNGN
-0.00030 (-23.08%)
Jan 30 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.00 - 0.00
52 week 0.00 - 0.31
Open 0.00
Vol / Avg. 93,130.00/569,963.00
Mkt cap 40,246.00
P/E     -
Div/yield     -
EPS -2.41
Shares 36.62M
Beta 2.55
Inst. own 50%
Mar 24, 2015
Q4 2014 Tengion Inc Earnings Release (Estimated) Add to calendar
Nov 14, 2014
Q3 2014 Tengion Inc Earnings Release

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -618.10% -99.20%
Return on average equity - -
Employees 25 -
CDP Score - -


Suite G, 3929 Westpoint Blvd.
United States - Map
+1-336-7225855 (Phone)
+1-302-6555049 (Fax)

Website links


Tengion, Inc. is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ. The Company, by using its Organ Regeneration Platform, it creates neo-organs using patient�s own cells. The Company, based on its clinical and preclinical experience is leveraging its Organ Regeneration Platform to develop Neo-Kidney Augment for patients with advanced chronic kidney disease and Neo-Urinary Conduit for bladder cancer patients who are in need of a urinary diversion. The Company�s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.

Officers and directors

David I. Scheer Independent Chairman of the Board
Age: 61
Carl-Johan Dalsgaard M.D. Independent Director
Age: 56
Diane K. Jorkasky M.D. Independent Director
Age: 61
Richard E. Kuntz M.D. Independent Director
Age: 57
Lorin Jeffry Randall Independent Director
Age: 70